K
v
ire
.com
←
Back
Night
Docs
Library
Review
…
Author
Mark G. Kris
also known as Kris, Mark, Kris, Mark G., M G Kris
Memorial Sloan Kettering Cancer Center · Cornell University · Weill Cornell Medicine · AstraZeneca (United Kingdom)
About this author
Works
1,386
Cited by
101,324
h-index
149
i10
537
ORCID ↗
Top papers
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao, Vincent A. Miller, Maureen F. Zakowski, et al.
·
2004
·
Proceedings of the National Academy of Sciences
↗ 4,337
OA
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao, Vincent A. Miller, Katerina Politi, et al.
·
2005
·
PLoS Medicine
↗ 3,521
OA
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Ethan Basch, Allison M. Deal, Mark G. Kris, et al.
·
2015
·
Journal of Clinical Oncology
↗ 2,610
OA
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, et al.
·
2003
·
JAMA
↗ 2,535
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, et al.
·
2013
·
Clinical Cancer Research
↗ 2,454
OA
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Ethan Basch, Allison M. Deal, Amylou C. Dueck, et al.
·
2017
·
JAMA
↗ 2,265
OA
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, et al.
·
2014
·
JAMA
↗ 1,733
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
William Pao, Theresa Y. Wang, Gregory J. Riely, et al.
·
2005
·
PLoS Medicine
↗ 1,524
OA
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Roy S. Herbst, Diane Prager, Róbert Hermann, et al.
·
2005
·
Journal of Clinical Oncology
↗ 1,497
OA
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi, Francisco Sánchez-Vega, Konnor La, et al.
·
2018
·
Journal of Clinical Oncology
↗ 1,409
OA
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford, Howard Ozer, Ronald G. Stoller, et al.
·
1991
·
New England Journal of Medicine
↗ 1,401
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr, et al.
·
2000
·
Journal of Clinical Oncology
↗ 1,371